<code id='F836D51F46'></code><style id='F836D51F46'></style>
    • <acronym id='F836D51F46'></acronym>
      <center id='F836D51F46'><center id='F836D51F46'><tfoot id='F836D51F46'></tfoot></center><abbr id='F836D51F46'><dir id='F836D51F46'><tfoot id='F836D51F46'></tfoot><noframes id='F836D51F46'>

    • <optgroup id='F836D51F46'><strike id='F836D51F46'><sup id='F836D51F46'></sup></strike><code id='F836D51F46'></code></optgroup>
        1. <b id='F836D51F46'><label id='F836D51F46'><select id='F836D51F46'><dt id='F836D51F46'><span id='F836D51F46'></span></dt></select></label></b><u id='F836D51F46'></u>
          <i id='F836D51F46'><strike id='F836D51F46'><tt id='F836D51F46'><pre id='F836D51F46'></pre></tt></strike></i>

          Wikipedia

          Wikipedia

          author:Wikipedia    Page View:143
          An FDA sign — health policy coverage from STAT
          Sarah Silbiger/Getty Images

          WASHINGTON — There’s about to be a new acronym in town.

          The Food and Drug Administration is in the final stages of cementing sweeping changes to the Office of Regulatory Affairs, which oversees inspections and compliance for all its regulated products, according to three people familiar with the planning.

          advertisement

          That overhaul includes a new name: Meet the Office of Inspections and Investigations.

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In

          focus

          Tori Bowie and the unacceptable rates of Black maternal death
          Tori Bowie and the unacceptable rates of Black maternal death

          AlastairGrant/APThehorrorstoriesofBlackwomendyingorcomingclosetodeathinchildbirthneverseemtostopcomi

          read more
          BIO to announce reorganization, senior leaders expected to depart
          BIO to announce reorganization, senior leaders expected to depart

          BIOisproceedingwitharestructuringafteritsnewCEOtookover.LaneTurner/TheBostonGlobeWASHINGTON—T

          read more
          The cancer drug shortage isn’t new — and neither are the solutions
          The cancer drug shortage isn’t new — and neither are the solutions

          PreparingachemotherapytreatmentatDukeCancerCenterinDurham,N.C.GerryBroome/APAyounggirl,maybe5or6year

          read more

          With competition flaring, obesity drug hits goal in liver disease study

          AdobeLONDON—AdrugindevelopmentasaweightlosstreatmentsucceededinaPhase2studyinaseriouslivercondition,